Skip to main content
. 2020 May 12;3(3):e00131. doi: 10.1002/edm2.131

FIGURE 3.

FIGURE 3

Changes to hepatic steatosis using TE with CAP based on treatment with SGLT‐2 inhibitors or GLP‐1 analogues. There was a significant reduction in CAP in patients receiving SGLT‐2 inhibitors but not GLP‐1 analogues (A, B). Grey boxes represent CAP measurements at baseline, and white boxes represent CAP measurements at the 6‐mo follow‐up (A). Individual patient data for baseline and 6‐mo measurements as quantified using CAP (B)